Changing BDNF Levels with Depression Treatment
Doctor Abraham Zangen describes how transcranial magnetic stimulation (TMS) may affect levels of BDNF in the hippocampus, thereby treating depression.
One of the markers today associated with depression is reduction in brain-derived neurotrophic factor [BDNF], which is a protein important for neural plasticity for the ability of the brain to learn to change. So this factor which again is a big protein is involved in many processes in the brain. It was found that in depressive subjects the levels of this protein are lower especially in a region called the hippocampus Antidepressant drugs - repeated use of antidepressant drugs causes elevation of this factor. We actually studied what happens if we induce a reduction in this factor in animals and looked at the battery of behavioral tests and found that reduction of this factor would cause depressive-like behavior in animal models. Now, what brain stimulation is doing, electrical stimulation or magnetic stimulation that I mentioned before is to actually increase this factor in hippocampus and we found this to happen only after repeated stimulations. It is not enough to give one session of brain stimulation to induce increased BDNF (brain-derived neurotrophic factor) levels, you need several sessions and also the behavior, I mean, the normalization of behavior in animal models or in humans is shown only after repeated stimulation. There is correlation between the elevation of the brain-derived neurotrophic factor levels in the hippocampus and the normalization of the behavior.
bdnf, tms, transcranial, magnetic, stimulation, depression, neural plasticity, brain stimulation, brain derived neurotrophic factor, animal models, hippocampus, electrical stimulation, abraham, zangen
Doctor Abraham Zangen discusses a treatment developed by his group that uses transcranial magnetic stimulation (TMS) to treat depression.
Doctor Abraham Zangen discusses two techniques for treating depression, which involve electrically stimulating the brain - transcranial magnietic stimulation (TMS) and deep brain stimulation (DBS).
Doctor Abraham Zangen discusses how transcranial magnetic stimulation (TMS) can stimulate different areas of the brain and treat depression.
Doctor Abraham Zangen point out that dopamine and BDNF levels in the nucleus accumbens and hippocampus of depressed patients are different. Treatment with antidepressants or ECT can impact these differences.
Professor Bruce McEwen introduces BDNF, a class of neurotrophic molecules released by excitatory neurotransmission and associated with key process and disorders.
Brain-derived neurotrophic factor (BDNF) is mainly expressed in the central nervous system. It has attracted much attention as a depression candidate gene.
Individual variations in antidepressant treatment outcomes.
Research continues to show that stem cells could be harnessed for therapeutic purposes.
Professor Bruce McEwen discusses the remodeling of dendrites, which are affected by BDNF, TPA, cell-adhesion molecules, and a number of other factors.
Doctor Abraham Zangen discusses the key structures underlying the brain reward system, a complex neural network that includes the nucleus accumbens and hippocampus.